Cargando…

Development of Interstitial Lung Disease Among Patients With Atrial Fibrillation Receiving Oral Anticoagulants in Taiwan

IMPORTANCE: There are emerging concerns from case reports and pharmacovigilance analyses of a possible risk of interstitial lung disease (ILD) associated with the use of factor Xa (FXa) inhibitors. OBJECTIVE: To evaluate the risk of incident ILD associated with the use of oral anticoagulants (OACs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Yi-Hsin, Chao, Tze-Fan, Chen, Shao-Wei, Lee, Hsin-Fu, Chen, Wei-Min, Li, Pei-Ru, Yeh, Yung-Hsin, Kuo, Chi-Tai, See, Lai-Chu, Lip, Gregory Y. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682427/ https://www.ncbi.nlm.nih.gov/pubmed/36413365 http://dx.doi.org/10.1001/jamanetworkopen.2022.43307

Ejemplares similares

Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
por: Chang, Chia-Yu, et al.
Publicado: (2017)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Atrial fibrillation and its arrhythmogenesis associated with insulin resistance
por: Chan, Yi-Hsin, et al.
Publicado: (2019)

The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

The CHA(2)DS(2)-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants
por: Lee, Kuang-Tso, et al.
Publicado: (2018)

Young Male Patients with Atrial Fibrillation and CHA(2)DS(2)-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study
por: Chan, Yi-Hsin, et al.
Publicado: (2016)

Prothrombin Time-International Normalized Ratio Predicts the Outcome of Atrial Fibrillation Patients Taking Rivaroxaban
por: Chao, Tze-Fan, et al.
Publicado: (2022)

Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy
por: Søgaard, Mette, et al.
Publicado: (2022)

A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan
por: Wu, Lung-Sheng, et al.
Publicado: (2016)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies
por: Chang, Shang-Hung, et al.
Publicado: (2014)

Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
por: Lee, Hsin-Fu, et al.
Publicado: (2020)

Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Patients and Their Physician’s Perspectives About Oral Anticoagulation in Patients With Atrial Fibrillation Not Receiving an Anticoagulant
por: Cannon, Christopher P., et al.
Publicado: (2023)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2019)

Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants
por: Lip, Gregory Y. H., et al.
Publicado: (2022)

Risk of Bleeding and Stroke with Oral Anticoagulation and Antiplatelet Therapy in Patients with Atrial Fibrillation in Taiwan: A Nationwide Cohort Study
por: Chen, Pei-Chun, et al.
Publicado: (2015)

The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor
por: Chan, Yi-Hsin, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study
por: Liu, Shin-Huei, et al.
Publicado: (2023)

Association evidence of CCTTT repeat polymorphism in the iNOS promoter and the risk of atrial fibrillation in Taiwanese
por: Hsu, Lung-An, et al.
Publicado: (2017)

Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis
por: Lane, Deirdre A., et al.
Publicado: (2018)

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding
por: Lip, Gregory Y. H., et al.
Publicado: (2021)

Aldehyde Dehydrogenase 2 Ameliorates Chronic Alcohol Consumption-Induced Atrial Fibrillation through Detoxification of 4-HNE
por: Hsu, Lung-An, et al.
Publicado: (2020)

Microsatellite Polymorphism in the Heme Oxygenase-1 Gene Promoter and the Risk of Atrial Fibrillation in Taiwanese
por: Hsu, Lung-An, et al.
Publicado: (2014)

Frailty, Home Time, and Health Care Costs in Older Adults With Atrial Fibrillation Receiving Oral Anticoagulants
por: Lin, Kueiyu Joshua, et al.
Publicado: (2023)

Editorial to “The differences of atrial thrombus locations and variable response to anticoagulation in non‐valvular atrial fibrillation with ventricular cardiomyopathy”
por: Chung, Wei‐Hsin, et al.
Publicado: (2020)

Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients
por: Deitelzweig, Steven, et al.
Publicado: (2019)

MMP9 Rs3918242 Polymorphism Affects Tachycardia-Induced MMP9 Expression in Cultured Atrial-Derived Myocytes but Is Not a Risk Factor for Atrial Fibrillation among the Taiwanese
por: Hsiao, Fu-Chih, et al.
Publicado: (2016)

Catheter Ablation With Morphologic Repetitiveness Mapping for Persistent Atrial Fibrillation
por: Lin, Chin-Yu, et al.
Publicado: (2023)

Risk of atrial fibrillation in patients with pneumoconiosis: A nationwide study in Taiwan
por: Hu, Wei‐Syun, et al.
Publicado: (2019)

Modified Taiwan Atrial Fibrillation Score for the Prediction of Incident Atrial Fibrillation
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function
por: Pham, Phuong, et al.
Publicado: (2020)

Analysis of Anticoagulation Therapy and Anticoagulation-Related Outcomes Among Asian Patients After Mechanical Valve Replacement
por: Huang, Jo-Ting, et al.
Publicado: (2022)

Type of atrial fibrillation and outcomes in patients without oral anticoagulants
por: Ren, Jiameng, et al.
Publicado: (2020)

Stroke and Bleeding Risk Assessment in Atrial Fibrillation: Where Are We Now?
por: Kuo, Ling, et al.
Publicado: (2021)

Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non–vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage
por: Tsai, Chuan-Tsai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_etlulbl3cfpinh92gav1a36gri